Share this article on:

Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors

Benhammou, Valériea; Warszawski, Josianea,b,c,d; Bellec, Stéphaniec,e,f; Doz, Françoisg,h; André, Nicolasi,j; Lacour, Brigittek; Levine, Martinel; Bavoux, Françoisem; Tubiana, Rolandn; Mandelbrot, Laurento; Clavel, Jacquelinec,e,f; Blanche, Stéphaneh,pon behalf ANRS-Enquête Périnatale Française


There is an error in the list of participants in the ANRS French Perinatal Cohort (EPF) that appears in the Acknowledgement section on page 2175 of this paper [1]. The first name initial for Carbillon should be “L.” and not “Francois F.”

AIDS. 26(8):1047, May 15th, 2012.

doi: 10.1097/QAD.0b013e328311d18b
Clinical Science

Context: Long-term studies of tolerance to perinatal exposure to antiretroviral nucleoside reverse transcriptase inhibitors are required, in view of the potential genotoxicity of some of these molecules.

Objective: To evaluate the incidence of cancers in uninfected children born to HIV-infected mothers.

Method: Cancers were detected in a nationwide prospective cohort of children born to HIV-infected mothers by standardized questionnaire during the prospective follow-up period of 2 years; thereafter, they were detected by spontaneous pharmacovigilance declaration and by crosschecking data with the national registries of childhood cancer. Standardized incidence ratio for incidence comparisons with general population.

Results: Ten cases of cancer were detected among the 9127 exposed HIV-uninfected children (median age: 5.4 years, 53 052 person-years of follow-up). The overall incidence did not differ significantly from that expected for the general population: 10 cases observed versus 8.9 and 9.6 expected depending on whether 1990–1999 or 2000–2004 national rates were used as reference [standardized incidence ratio of 1.1 (0.3–1.5) and 1.0 (0.5–1.9)]. Five cases of central nervous system cancer were observed (standardized incidence ratio of 3.1 [1.0–7.2] P = 0.05 and 2.4 [0.8–5.6], P = 0.12). The relative risk of cancer for children exposed to didanosine–lamivudine combination was higher than that for zidovudine monotherapy [hazard ratio: 13.6 (2.5–73.9)].

Conclusion: This study did not evidence an overall increase in cancer risk in nucleoside reverse transcriptase inhibitor exposed children until 5 years of age. Results suggesting associations with specific nucleoside reverse transcriptase inhibitor combinations need further investigations. A longer surveillance, including differential analysis of the different cancer sites and various nucleoside reverse transcriptase inhibitors administered is warranted.

aInserm, U822, Le Kremlin-Bicêtre, France

bINED, Paris, France

cUniversité Paris-Sud, Faculté de Médecine Paris-Sud, Le Kremlin-Bicêtre, France

dAssistance Publique – Hôpitaux de Paris (AP-HP), Hôpital Bicêtre, Epidemiology and Public Health Service, France

eRegistre National des Hémopathies Malignes de l'Enfant (French National Registry of Childhood Hematopoietic Malignancies), INSERM U754, France

fINSERM U754, Villejuif, France

gInstitut Curie, Service de Cancérologie Pédiatrique Paris, France

hFaculté de Médecine René Descartes, Equipe d'Accueil EA 3620, Université Paris V, Paris, France

iAssistance Publique – Hôpitaux de Marseille, Hôpital de la Timone, Marseille, Service d'oncologie pédiatrique, France

jINSERM UMR 911, Centre de Recherche en Oncologie Biologique et Oncopharmacologie, Université Aix-Marseille, France

kRegistre National des Tumeurs Solides de l'Enfant (French Registry of Childhood Solid Tumors), Centre Hospitalier et Universitaire de Nancy, Nancy, France

lAP-HP, Hôpital Robert Debré, Paris, Service d'Hématologie Pédiatrique, France

mAP-HP Hôpital Saint Vincent de Paul, Paris Centre de Pharmacovigilance Pédiatrique, France

nAP-HP Hôpital Pitié Salpétrière, Paris Service de Maladie Infectieuses, France

oAP-HP Hôpital Louis Mourier, Colombes, Service de Gynécologie-Obstétrique, France

pAP-HP Hôpital Necker-Enfants Malades, Paris, Service d'Immunologie Hématologie Pédiatrique, Paris, France.

*List of authors given in acknowledgements.

Received 18 April, 2008

Revised 22 July, 2008

Accepted 23 July, 2008

Correspondence to Stéphane Blanche, Hôpital Necker-Enfants Malades, Paris, France. Tel: +33 1 4 49 48 24; fax: +33 1 44 49 48 18; e-mail:

The prevention of perinatal transmission of HIV by antiretroviral treatment during pregnancy is remarkably effective [1]. This treatment was initially based on zidovudine monotherapy [2], but current recommendations propose the use of combinations of antiretroviral drugs generally consisting of at least two nucleoside reverse transcriptase inhibitors (NRTIs) [3,4]. The most widely used NRTI combination is zidovudine–lamivudine together with a protease inhibitor, but six NRTIs (zidovudine, lamivudine, didanosine, stavudine, abacavir and emtricitabine) and one nucleotide reverse transcriptase inhibitor (tenofovir) have now been licensed, leading to a large number of combinations. Among NRTIs, zidovudine is the antiretroviral molecule for which tolerance during pregnancy has been best studied [5,6]. Exposure to prophylactic zidovudine during pregnancy is associated with a series of biological perturbations, but only rare clinical events in children. The main feature is a usually mild and reversible anemia, but persistent perturbations of other hematological lineages have been described in several cohorts [7–9]. Being a nucleoside analogue, zidovudine has a significant affinity for DNA in mammals [10,11]. The potential genotoxicity of these drugs is supported by diverse experimental data: it differs between molecules and involves a complex network of events that may lead to genomic instability due to incorporation of the drug into the DNA, mutagenesis, clastogenesis and telomere attrition [11]. Following in utero exposure to zidovudine in rodent models, a series of genotoxicity markers can be found in the offspring, including zidovudine integration into DNA, mutagenesis and shortened telomeres [12–16]. Dose-dependent tumor induction has been observed in CD-1 mice [15]. This observation, which was not initially found with lower doses [17], has subsequently been confirmed in other studies in B6C3F1 mice and F344 rats [18]. According to the International Agency for Research on Cancer, evidence for carcinogenicity from studies in laboratory animals is sufficient to consider zidovudine being classified as ‘possibly carcinogenic to humans’ (group 2B) [19]. The other NRTIs have been much less studied. In addition to the individual genotoxicity profile intrinsic to each molecule, the NRTIs combinations could theoretically result in additive or synergistic toxicity [11]. In chronically infected patients, there is no evidence of cancer induction by the use of NRTI sometimes for very long periods up to 20 years. On the contrary antiretroviral combinations induced a strong reduction of HIV-related cancers [20].

To date two studies with a limited number of children and follow-up found no cases of cancer in NRTI-exposed children [21–23]. Authors argued for larger and longer surveys based on long-term ‘noninvasive’ monitoring for these healthy children.

The French Perinatal Cohort [Enquête Périnatale Française (EPF)] has included more than 11 000 mother–child pairs since 1984, 80% of whom have been exposed to perinatal NRTIs. Our aim was to estimate the incidence of cancers in uninfected children in utero exposed to antiretroviral therapy, using both a system of active follow-up and crosschecking with registries.

Back to Top | Article Outline

Patients and methods

The prospective Enquête Périnatale Française cohort

The French perinatal survey (EPF) is a prospective multicenter study following HIV-infected pregnant women and their children [24]. Uninfected children, who now account for almost 99% of neonates born to HIV-infected mothers, are followed from birth until the age of 2 years through standardized questionnaires completed by physicians according to national recommendations for the management of children born to HIV-infected mothers [4]. An open system of pharmacovigilance has been established for after the end of the active follow-up period and investigators are asked to notify the coordinating center (together with the health authorities) of all severe events that they learn of in children from the cohort. In parallel, the investigators are asked to make parents aware of the importance of notifying any new medical team treating their child of that child's perinatal history. Among the 12 074 live born infants included in the metropolitan EPF sites cohort between 24 September 1984 and 1 May 2007, 11 553 were considered as HIV-1 uninfected. Among them, 9127 children were exposed to at least one NRTI at during one or more of the prepartum, perpartum or postpartum phases since 1990 (274 during the per and postpartum phases exclusively) (Fig. 1).

Fig. 1

Fig. 1

Participation in the study is voluntary and requires parental consent. The study protocol has been approved by the ethics and regulatory committees, as laid down in French law covering such research.

Back to Top | Article Outline

Antiretroviral treatments

Participating physicians are asked to follow national guidelines for the treatment of pregnant women with antiretroviral drugs; they are, however, free to make their own decisions concerning the treatment of pregnant women in the best interests of the woman and child's health. Successive French recommendations have been similar to those in North America and in other European countries [3–4].

Prophylaxis was initially based on zidovudine monotherapy. Treatment gradually became more complex, due to the use of combinations of nucleoside analogues (mostly zidovudine–lamivudine), and then with the development of multitherapies (combinations of two nucleoside analogues and a protease inhibitor or a nonnucleoside inhibitor of reverse transcriptase). Regardless of the treatment received by the mother during pregnancy, zidovudine perfusion is recommended during delivery and the child is treated with zidovudine for 4–6 weeks postpartum. The treatment of the child is sometimes strengthened by the addition of one or several other antiviral molecules in cases of a high residual risk of transmission.

Back to Top | Article Outline

Cancer detection

We looked for cases of cancer: standardized follow-up questionnaire during the 24 first months; spontaneous notification by the clinicians participating in the EPF cohort or by the network of pediatric hemato-oncologists who were targeted by an information campaign; crosschecking with the French national childhood cancer registries: the National Registry of Childhood Hematopoietic Malignancies (RNHE), which started cancer registration in 1990, and the National Registry of Childhood Solid Tumors (RNTSE), which started in 2000 [25] to identify whether cancers notified in registries occurred in eligible children born in EPF sites. The registries include nominative information, but the coordinating EPF center does not. Concordance of date of birth, sex and place of birth was used to crosscheck between children notified in registries and those in the EPF database. The 618 potential concordant entries were then individually checked by contacting each maternity or pediatric EPF site to identify whether or not the two sets of data corresponded to the same child. At the time of this analysis, the national registries were considered exhaustive for all pediatric (0–15 years) cases of cancer diagnosed in France up to 31 December 2004.

A group of pediatric cancer experts (including the coauthors F.D., N.A., J.C. and B.L.) was set up to collect the information required for the validation of each case. Classifications of detected cancer are presented according to the International Classification of Childhood Cancer [26]. The last evaluation of cancer detection was made on 1 May 2007

Back to Top | Article Outline


The total follow-up time for uninfected children, expressed in person-years, was calculated for the 9127 uninfected live-born children exposed to nucleoside analogues, alone or in combination. We compared the incidence of cancers in the EPF cohort with that in the general population by indirect standardization. The standardized incidence ratios (SIRs) were obtained by dividing the number of observed cases in the cohort by the number of expected cases calculated by applying the reference rate for each year of age to the cohort person-years of this age. We took as reference rates the two different sets of incidence rates that were available in France, that is those estimated by the French regional pediatric cancer registries (one-third of the French territory over the decade 1990–1999 [25]), and the first national estimates provided for the 2000–2004 period by the French national childhood cancer registries RNHE and RNTSE (unpublished data). Confidence intervals (95% CI) for SIR were estimated using Byar's method [27].

Univariate and multivariate survival analyses were performed for the subpopulation of children born to mothers who received antiretroviral therapy during pregnancy (N = 8853), to identify perinatal factors associated with cancer occurrence. Survival curves were compared by using logrank tests. The cumulative incidence of cancer was estimated and plotted by the Kaplan–Meier method. Noncolinear variables found to be associated with cancer with a logrank P-value less than 0.10 were included in a multivariate Cox proportional hazards model. Statistical analyses were performed using the Stata software (Stata Corp., College Station, Texas, USA).

Back to Top | Article Outline


Description of the cohort

Overall, antiviral exposure (type, doses, timing) data were available for statistical analysis for 10 979 uninfected children live born at mainland French EPF sites between 24 September 1984 and 1 May 2007, that is 95.2% of children notified to the coordinating center. Of these children, 9127 (83%) were exposed to at least one nucleoside analogue at some time during pregnancy and/or the postnatal period (Figs 2 and 3). The uses of combinations progressively increased (e.g. 67% in 2000) and were given to nearly all mothers who delivered in 2006. The third molecule was a nonnucleoside reverse transcriptase inhibitor (NNRTI) in 1015 women and a protease inhibitor in 3792 women. Protease inhibitors were mainly nelfinavir-boosted (1828 women) and ritonavir-boosted lopinavir (1117 women).

Fig. 2

Fig. 2

Fig. 3

Fig. 3

The median duration of antiretroviral treatment during pregnancy was 11 [interquartile range (IQR): 7–18] weeks for mothers who received only zidovudine monotherapy (n = 2115) and 20 (IQR: 11–37) weeks for mothers who received combinations of drugs (n = 6644). Treatment began before or during the first trimester of pregnancy (before 14 weeks of amenorrhea) in 31.5% of mothers, during the second or third trimester (14 weeks of amenorrhea) and later) for 64.5% and was solely perpartum and postnatal for 3.0% of mother–child pairs (Fig. 2). The timing of treatment initiation during pregnancy was unknown (missing data) for 1.0% of the mother–child pairs. Among children exposed during pregnancy, 98% received postnatal prophylaxis consisting mostly (82%) of zidovudine monotherapy for 4 or 6 weeks, and of zidovudine–lamivudine for most other children.

Back to Top | Article Outline

Cancers detected and circumstances of their detection

By 1 May 2007, 10 cases of cancer had been identified in the cohort: three cases of acute lymphoblastic leukemia, two cases of retinoblastoma (one bilateral, one unilateral), two cases of pineoblastoma, three cases of glioma (one cerebellar pilocytic astrocytoma, one biopsied chiasmatic tumor and one intraventricular fibrillary astrocytoma) (Table 1). Diagnostic procedures and treatment were administered in specialized pediatric oncology centers for all children. The mean age at onset of cancer was 54 months (range: 10–132), with six boys and four girls affected. The child with the chiasma tumor suffered from familial neurofibromatosis type 1 (NF1 or von Recklinghausen's disease) which predisposes to this type of cancer. A constitutional mutation in the RB1 gene was identified in the child presenting with bilateral retinoblastoma. The two tumors in children under the age of 2 years were both declared as part of the active follow-up of the cohort. The spontaneous notification system notified the coordinating center about the other eight. No additional cases were identified by crosschecking with the national register after having checked the identifiers of 618 children with concordant date and place of birth and sex. Conversely, all cases of hematopoietic malignancy from 1990 and all solid tumors from 2000 notified directly to the EPF cohort were also notified by the national registries. No case was observed in the 1852 uninfected children included in the EPF cohort not exposed to perinatal antiretroviral therapy.

Table 1

Table 1

All the children with tumors were exposed to nucleoside analogues during pregnancy: four were exposed to zidovudine monotherapy, three to a combination of zidovudine and lamivudine, two to a combination of zidovudine, didanosine and lamivudine and one to a combination of didanosine and lamivudine. Concerning the other classes of antiretroviral treatments, two mothers received nelfinavir and one ritonavir. Two children received two doses each of nevirapine.

Back to Top | Article Outline

Comparison of cancer incidence among exposed children included in Enquête Périnatale Française cohort with that in the general population

The present analysis was based on all 9127 children exposed at any time (prepartum, intrapartum, postpartum) to at least one NRTI between September 1984 and May 2007 (Acknowledgements); this represents 53 052 exposed person-years for ages 0–15 years old, and 10 746 for the period 2000–2004 when the national registries RNHE and RNTSE were both exhaustive.

The number of cancer cases observed in the cohort (10 cases) did not differ significantly from the expected numbers based on regional (8.9 cases; SIR = 1.1 [0.5–2.1]) or national (9.6 cases; SIR = 1.0 [0.5–1.9]) reference rates (Table 2). The result was similar when the analysis was restricted to children born and followed up during the period 2000–2004 with three cases of cancer observed for 2.1 or 2.3 expected. However, five of the tumors involved the central nervous system (CNS), whereas only 1.6 or 2.1 would be expected using the 1990–1999 regional and 2000–2004 national references [SIR = 3.1 (1.0–7.2), P = 0.05 and 2.4 (0.8–5.6), P = 0.12, respectively] (Table 2). Similar estimates were obtained for the period 2000–2004 when crosschecking with national registries became possible. Two of the five tumors of the CNS were pinealoblastomas. A third tumor was unusual: an intraventricular fibrillary astrocytoma. Conversely, 4.1 cases of other cancers (sympathetic nervous system tumors, renal tumors or other tumors) were expected over the study period and none was observed.

Table 2

Table 2

Back to Top | Article Outline

Factors associated with risk of cancer among children exposed to prenatal antiretroviral treatment

Among the 8853 children exposed to NRTIs during the prepartum phase, cancer was not associated with maternal geographical origin, drug addiction, last viral load before delivery or sex of the child. Prematurity was associated with cancer (P-logrank = 0.0018), with a hazard ratio (HR) of 10.0 (95% CI 2.1–48.5) for severe prematurity (<33 weeks) compared with full-term delivery. Combinations including both zidovudine and lamivudine, with or without other molecules except didanosine, were not associated with a higher risk of cancer than zidovudine monotherapy. The risk of cancer was significantly higher [HR: 12.5 (2.4–66.1)] in the 365 children exposed simultaneously to NRTI combinations including at least both lamivudine and didanosine, than the 2147 children exposed only to zidovudine monotherapy (Table 3 and Fig. 4). In utero exposure to the protease inhibitors nelfinavir or lopinavir was not significantly associated with a higher risk of cancer. Prematurity and lamivudine–didanosine combinations remained independently associated with cancer in a multivariate Cox model (Table 3). Adjustments for maternal CD4 cell count as a continuous variable did not change the results.

Table 3

Table 3

Table 3

Table 3

Fig. 4

Fig. 4

Back to Top | Article Outline


The long-term tolerance of anti-HIV perinatal prophylaxis should be evaluated, but there are several obstacles to the implementation of an epidemiological surveillance system able to detect potential adverse events among uninfected children. After the first 2 years of life (standardized follow-up), the children diagnosed as HIV-uninfected are generally no longer followed by the medical team that managed the perinatal period. For understandable reasons, the parents do not necessarily reveal the history of this perinatal exposure, or do not see the utility of doing so. Crossmatching of children included in HIV perinatal cohorts with children notified to national specific registries, as proposed recently by UK team for cancer screening [22], may be an appropriate approach to detecting such events without an active follow-up.

With 10 cases of cancer observed to date in our cohort, the overall risk of cancer was not greater than that for the general population [25,28], as previously suggested on two smaller cohorts [21–23].

In the EPF cohort, cancer cases were actively detected through the 2-year standardized follow-up, spontaneous declarations and crossmatching with national registries. Despite the large number of children included, the statistical power of the study was limited. With a power of 80%, and an α risk at 5%, the size of the present study allowed detection of SIR higher than two for all cancers, three for leukemia and four for CNS tumors. The median age of exposed children was only 5.4 years old (IQR: 2.9–8.3); a longer follow-up is warranted.

Five CNS tumors were observed, whereas only 1.6–2.1 (according to the reference rate used) were expected, and the difference was close to statistical significance (P = 0.05 to 0.12). The analysis restricted to the period 2000–2004 for which the French register of childhood cancers was exhaustive gave similar results with two observed tumors versus 0.3–0.4 expected. We used the two different reference rates that were available in France. For CNS tumors, the national rates produced by the national registries in the recent period 2000–2004 are higher than those of the previous regional registries, which covered around 30% of the French territory in 1990–1999. This is probably due to the increase in quality of notification and registration that came with the development of computerized hospital files, but an increase in incidence cannot be ruled out. Both incidence rates are consistent with those published at the same period in other western countries. The annual age-standardized incidence rate estimated in the 1990s by the French regional registries was 29.1 cases per million [23] and 29.9 per million in Europe over the 1988–1997 period [29]. The rates estimated by the French national registries for 2000–2004 (36.1 per million; unpublished data) were also close to the figures reported in the United States ( and Germany ( (32.9 and 31 per million, respectively) for the same period.

The observation of two cases of pineoblastoma among the five CNS tumors, together with two cases of retinoblastoma, is worrying. Pineoblastoma is a rare tumor in children, with a mean of only three cases per year reported in the French national registry of solid tumors. It is also one of the secondary tumors that may affect children with hereditary retinoblastoma [30]. Another tumor observed in this cohort, an intraventricular fibrillar astrocytoma or ‘holoventricular low-grade glioma’, is extremely rare [31].

Unexpectedly higher risk of cancer was observed for children who were exposed to combinations including didanosine–lamivudine than for those exposed to zidovudine monotherapy (adjusted HR = 13.6 [2.5–73.9]). Didanosine–lamivudine was given to less than 4% of treated women of the cohort and is associated with one-third of tumors. Given the small number of cancer events seen, interpretation of this difference must be cautious. We used a global logrank test with a single P-value to study the association between cancer incidence and the type of NRTI combinations ever administered during pregnancy, and not multiple tests to compare each of the five combination to the reference category (exclusive monotherapy). This P-value was very low (<0.0001) and remained lower than the Bonferroni corrected P-value threshold (0.05/8 = 0.006) taking into account eight statistical tests as we also tested separately the association between cancer incidence and seven molecules. Moreover, the hazard ratio associated with ‘didanosine and lamivudine’ was very high (12.5) and the lower bound of 95% CI strongly higher than the unity: 95% CI 2.4–66.1. Interestingly, a rare neuroectormic tumor (melanotic progonoma tumor) was recently diagnosed in a child exposed to a didanosine–lamivudine combination but not included in the EPF cohort (D. Plantaz, MD, Grenoble, France, personal communication).

A scale of genotoxicity for several NRTI combinations has been recently suggested on the basis of data from in-vitro mutagenesis assays for hypoxanthine–guanine phosphoribosyl transferase (HPRT) and thymidine kinase. The combinations were ranked as follows in decreasing order: zidovudine–didanosine > didanosine–lamivudine > zidovudine–lamivudine [32], but no comparative assay of these combinations in animal models of in utero exposure for tumor induction has been published. The combination of didanosine and lamivudine has been rarely prescribed for pregnant women. However, didanosine is now sometimes used as secondary or subsequent treatment and an increasing number of exposed children might be expected. In chronically HIV-1 infected adults and children, there is no evidence that zidovudine or other NRTIs alone or in combination contribute to the development of cancers despite 20 years of use. However, fetal and neonatal exposure may be a particular situation. Fetal and neonatal life is characterized by intense DNA replication activity and the activation of many oncogenes and tumor suppressor genes. Exposure to a genotoxic agent during this period may, therefore, have consequences different from those observed in adults [33]. In newborn and infants, exposure to zidovudine in utero leads to biological abnormalities, reflecting this genotoxicity. Thus, the integration of zidovudine into the DNA of neonates exposed to the drug in utero [34] may lead to mutagenesis [35] or other abnormalities, such as an increase in the frequency of micronuclei in erythrocytes [36] or an increase in heterochromatin dispersion [37]. The effects of other NRTIs alone or in combination have been less studied experimentally; nevertheless, some of them show effects in vitro similar to those of zidovudine and/or induce an additive or synergistic effect in combination. Our findings certainly highlight the need for further data concerning the genotoxicity of the various NRTI combinations.

Antiretroviral combinations are extremely powerful prophylaxis for HIV mother-to-child transmission but an effort to select genotoxicity-free combinations is justified.

Back to Top | Article Outline


All authors contributed significantly to this work. V.B. was the project coordinator. J.W. was the leader of EPF cohort, assisted by R.T., L.M. and S.B. for clinical aspects. J.C. and B.L. were the leaders of cancer registries, assisted by F.D., N.A. and M.L. for cases review. F.B. transmitted data from pharmacovigilance network. J.W., J.C., B.L. and S.Be. performed the statistical analysis. S.B. and J.W. initiated the project. Main writing process was done by V.B., J.W., J.C. and S.B. All authors reviewed and approved the papers before final submission.

We thank all families who agreed to participate in this study. We thank also Dr B. Pautard (Amiens), J. Tricoire (Toulouse), J.L. Stephan (Saint Etienne), S. Marthas (Dijon) and J. Grill (Villejuif), M. Zerah (Paris), I. Thuret (Marseille) for collaboration and data transmission.

The present work was supported by the Agence Nationale de Recherche sur le SIDA (ANRS) and the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS). French childhood cancer registries are supported by Institut de Veille Sanitaire (InVS) and Institut National pour la Santé et la Recherche Medicale (INSERM).

The authors have no conflicts of interest.

The following persons and institutions participated in the ANRS French Perinatal Cohort (EPF).

Aix-en-Provence: Brusquet Y., Opimel P., Tadrist B., Thevenieau D., Tramier D.; Amiens: Boulanger J.C., Douadi Y., Gondry J., Horle B., Pautard B., Roussel C., Schmidt J.L., Smail A., Vergne C.; Angers: Achard, Binelli C., Chennebault J.M., Fournie A., Grosieux P., Rialland X.; Argenteuil: Allizy C., Brault D., Genet P., Piquet, Rischebe, Tordjeman N.; Aubervilliers: Rozan M.A.; Basse-Terre: Couchy B., Sibille G., Sid Elmrabt S.; Bastia: Bastien, Belgodere, Colombani D., Lonrenzi, Pincemaille O., Salvetti A., Turquini; Bayonne: Bonnal F., Cayla C., Chabanier C., Guerre P., Hernandorena X.; Besançon: Bassignot A., Bettinger Lab M., Chirouze C., Estavoyer J.M., Leroy J., Maillet R., Schaal J.P.; Blanc Mesnil: Bajer A., Balde P.; Bobigny: Deny P.; Bondy: Benoist L., Carbillon, François F., Jeantils V., Lachassinne E., Rodriguez A., Uzan-Cohen M.; Bordeaux: Beylot J., Brun J.L., Douard D., Elleau C., Fleury H., Guyon F., Horovitz J., Lacoste, Leng J.J., Masquelier B., Morlat P., Pontgahet M., Ragnaud, Roux D., Schaeffer V.; Boulogne Billancourt: Gilles I., Zenaty D.; Bourg La Reine: Gantzer A.; Bullion: Colin-Gorki A.M.; Caen: Barjot P., Brouard J., Freymuth F., Goubin P., Muller G., Petit J., Six M.; Cayenne: Delattre P., Elenga N., Magnien C., Patient G.; Clamart: Bornarel D., Chambrin V., Clech L, Dehan M., Dommergues, Foix L., Frydman R., Keros L., Vial M.; Clichy: De Curtis A., Levardon M., Mazy F.; Colombes: Crenn-Hebert C., Engelmann P., Ferreira C, Floch-Tudal C., Gaba S., Joras M., Mandelbrot L., Marty L, Mazy F., Meier F.; Compiègne: Coicaud M., Lagrue A., Meriem D.; Corbeil Essonnes: Blasquez, Daveau C., Devidas A., Lotfy N.; Courbevoie: Botto, Bourdon P.; Creil: Cesbron P., Cordier F., Devulder G., Duval-Arnould M., Kingue-Ekollo C.; Creteil: Cortey A., Delacroix I., Elharrar B., Garrait V., Huraux-Rendu C., Paniel J.B., Touboul C.; Dijon: Buisson M., Guerin M.N., Kohli, Martha S., Reynaud I., Rousseau T., Sagot P.; Dourdan: Guth, Ercoli V.; Drancy: Boddaert M.; Dreux: Denavit M.F., Garnier J., Roudiere, Tribalat S.; Elbeuf: Lahsinat K., Paquet M., Pia P.; Evreux: Allouche C., Elhaik, Pascal C., Toure K.; Evry: Farvacque R., Grall F., Khanfar, May A., N'guyen R.; Fontainebleau: All-Issa K., Cosnefroy, Cote, Dallot M.C., Fillipini, Kalengi, Lhuillier P., Routier C.; Fort de France: Cabie A., Cecile W., Hatchuel Y., Mezin R., Ouka M., Sainte-Rose D.; Gonesse: Balde P., Dauptain G., Lobut J.B. Paindaveine; Ivry: Gervais A., Jault T., Jrad I., Pathier D., Lagny sur Marne, Agbo P., Algava G., Chalvon Dermesay A., David Ouaknine F., Gourdel B., Lanty C., Lerudulier C., Pfeiffer F.; Le Chesnay: Beal G., carre N, Harzic M., Hentgen,Jacquemot M.C., Lasfargues P., Messaoudi F., Teboul; Le Kremlin Bicêtre: Bader-Meunier B., Desfraissy J.F., Goujard C., Fridmann S., Peretti D.,; Le Lamentin: Chout, Monlouis M.; Lille: Bocket L., Codaccioni X., D'Angelo S., Delmas S., Hammou Y., Mazingue F., Vanderstichele S.; Limoges: Alain J., Denis F., Rogez S., Tabaste J.L., Venot C.; Longjumeau: Abbara A., Bailly Salin P., Blanchard I., Bronstein R., Dalvilic S., De San Pedro, Lemercier Y., Seaume H.; Lyon: Andre, Bertrand Y., Brochier C., Communal P.H., Cotte L., Kebaili K., Raudrant D., Ritter J., Roussouly M.J., Tardy, Thouarain V.; Mantes La Jolie: Berardi J.C., Botto C., DeLanete A., Doumet A., Furioli J., Granier F.,Grise, Salomon J.L., Wipff P.; Marseille: Blanc B., Cravello L., Deboisse P., Gallais H., Michel G., Pelloux, Tamalet C., Thuret I.; Meaux: Crumiere C., Demachy M.C., Karaoui L., Lefevre V., Michel F., Morel B.; Melun: Kleitz, Le Lorier B., Pauly-Ravelly I., Ponge B.; Meulan: Robichez, Seguy D.; Montfermeil: Camus M., Dehlinger M., Echard M., Mullard C., Rideau F., Ropert, Talon P.; Montpellier: Benos P., Boulot P., Bouzinger, Dechaud H., Guigue N., Laffargue F., Lalande M., Nicolas J., Reynes J., Segondy B., Sobierajski J., Vendrel; Montreuil: Heller-Roussin B., Saint-Leger S., Winter C.; Nancy: Delaporte M.O., Hubert C., May T., Neimann L., Schweitzer M.; Nanterre: Karoubi P., De Sarcus B.; Nantes: Auger M., Billaudel S., Brunet-François C., Boog G., Ferre V., Mechinaud F., Reliquet V., Winer N.; Neuilly sur Seine: Berterottiere D., Boto; Nice: Allione J., Bongain A., Cottalorda J., Couderc A., Deville A., Durant J., Galiba E, Gillet J.Y., Monpoux F.; Nîmes: Arnaut A., Barbuat C., Carles M.J., Dendale J., Ferrer C., Rouannet I., Sotto A.; Orléans: Arsac P., Barthez, Bondeux D., Mesnard L., Tescher M., Werner E.; Orsay: De Gennes C., Devianne, Drisset, Isart V., Razon; Perpignan: Bachelard G., Bachelard B., Medus M., Roudil; Pointe-à-Pitre: Bardinet F., Bataille, Duffilot D., Samar K, Sow M.T., Strobel M.; Poissy: Nisand I., Pavard, Rousset M.C.; Pontoise: Blum L., Danne O., Hervio P., Mouchnino G., Muray; Reims: Beguinot I., Graesslin O., Ingrand D., Munzer M., Quereux C., Remy G., Rouger C., Saniez D.; Rouen: Borsa-Lebas F., Brossard V., Buffet-Janvresse C., Clavier B., Debab Y., Marpeau L., Vannier J.P.; Saint-Etienne: Berger C., Billiemaz K., Fresard A., Pozzetto B., Stephan J.L., Varlet M.N.; Saint-Denis: Allemon M.C., Ekoukou D., Ghibaudo N., Khuong M.A., Luzolo A., Mechali D., Normand V., Poupard M.P., Retbi J, Retbi J.M., Rotten D., Seffert; Saint-Germain en Laye: Guyot B., Michelon, Narcy P.; Saint-Martin: Bissuel F., De Caunes F., Elouedghiri, Laborde O., Walter V.; Saint-Maurice: Jeny R., Robin; Sèvres: Belaisch-Allart J., Segard L.; Strasbourg: Brettes, Cheneau C., David, Dreyfus M., Entz-Werle N., Favreau J.J., Fischer P., Lang J.M., Langer B., Lutz P., Nisand I., Partisani M., Ritter, Treisser A., Vayssiere C., Weill M.; Suresnes: Clement, Colau J. C.; Toulouse: Armand, Berrebi A., Cohen M., De Coster P., Lecuyer I., Massip P., Perez-Baronne, Puel J., Reme J. M., Tricoire J.; Tours: Bansard H, Bastides F., Besnier J.M., Borderon J.C., Barin F., Lansac, Lionnet C., Marchand S Nau P, Pascale, Perrotin F., Potin J., Sigogneau H; La Trinité: Hugon N.; Vandoeuvre Les Nancy: Finance, Le Faou; Villejuif: Dussaix E.; Villeneuve Saint Georges: Bantsimba J., Bonnard C, Camuss A, Chace A., Guillot F., Jubin C., Maria B., Montaland F, Patey O., Richier L, Stampf F., Tran Van P.; Villepinte: Boulanger M.C., Broyard A., Caruge, Caubel P., Chitrit Y., Delassus J.L., Goldenstein, Le Pennec M., Poulen, Scart G., Zakaria A.; Vitry sur Seine: Lacroix-Coutry A., Sturbois G. Paris: ASE St Vincent de Paul, Commeau A.; Centre d'Hémobiologie Périnatale: Parnet Mathieu F.; Clinique Notre Dame de Bon Secours: Ayral D., De Kermadec S.; Groupe Hospitalier Cochin Tarnier Port-Royal: Brival, Cabrol D., Clement D., Compagnucci A., Desfeux P., Fikenstein, Firtion G., Goupil I., Henrion R., Launay O., Mandelbrot L., Pannier E., Pons J.C., Taulera; Hôpital Boucicaut: Bardin C., De Bievre P., Gras V., Labussiere E., Lafay Pillet M.C., Parat S., Taurelle R.; Hôpital Robert Debré: Bensaid Ph., Blot P., Boissinot Ch., Cotten G., Faye A., Levine M., Ottenwalter A., Oury J.F., Schaller F., Vilmer E.; Hôpital Trousseau: Chenon, Dollfus C., Gabarg-Chenon A., Tabone, Vaudre G., Institut de Puériculture Brune, Dubois M., Hôpital Lariboisière, Brunner C., Ciraru-Vigneron N., Peynet J., Colonna R., Sanson-Lepors, Truc; Hôpital des Métallurgistes: Cheynier J.M., Hatem-Gantzer G., Heller-Roussin B., Rami M.; Hôpital Rothschild: Fritel, Lebrette M.G., Nicolas J.C., Uzan M., Wallet A.; Hôpital Saint-Antoine: Bouillie J., Bui E., Carbonne B., Meyohas M.C., Milliez J., Rodriguez J., Schrub S.; Centre Hospitalier Pitié Salpetrière: Agut H., Bricaire F., Daher S., Diop A., Darbois Y., De Montgolfier, Dermer E., Deville-Chabrol A., Dommergues M., Huraux J.M., Noseda G., Pauchard M., Tubiana R., Hôpital Saint-Vincent de Paul, Boccara J.F., Francoual C., Krivine A., Lebon P.; Institut Mutualiste Montsouris: Carlus Moncomble C., Cohen H., Groupe Hospitalier Necker, Benachi A., Blanche S., Burgard M., Diop A. Parat S., Rouzioux C., Viard J.P.; Hôpital Saint-Michel: Aufrant C.; Hôpital Bichat-Claude Bernard: Allal, Bastian H., Batallan A., Brun-Vezinet F., Bernard, Damond F., Darai E., Faucher Ph., Longuet P., Madelenat P, Matheron S., Mazy F, Moreau G., Proust A., Rajguru M, Simon F.; Hôpital Tenon: Berkane N., Chaux M.C., Herve F., Lebrette M.G., Uzan S.

Back to Top | Article Outline


1. Gray GE, McIntyre JA. HIV and pregnancy. Br Med J 2007; 334:950–953.
2. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173–1180.
3. Perinatal HIV Guidelines Working Group. Public health service task force recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. 8 July 2008. [Accessed 1 August 2008].
4. French expert group for medical management of HIV infection. Highlights and recommendations 2006. [Accessed 1 August 2008].
5. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2007:CD003510.
6. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf 2007; 30:203–213.
7. Le Chenadec J, Mayaux MJ, Guihenneuc-Jouyaux C, Blanche S, Enquete Perinatale Francaise Study Group. Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants. AIDS 2003; 17:2053–2061.
8. European Collaborative Study. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1-infected mothers. AIDS 2004; 18:2009–2017.
9. Pacheco SE, McIntosh K, Lu M, Mofenson LM, Diaz C, Foca M, et al, Women and Infants Transmission Study. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study. J Infect Dis 2006; 194:1089–1097.
10. Lewis W. Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy. Antivir Ther (Lond) 2005; 10:M13–M27.
11. Olivero OA. Mechanisms of genotoxicity of nucleoside reverse transcriptase inhibitors. Environ Mol Mutagen 2007; 48:215–223.
12. Von Tungeln LS, Williams LD, Doerge DR, Shaddock JG, McGarrity LJ, Morris SM, et al. Transplacental drug transfer and frequency of Tk and Hprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine. Environ Mol Mutagen 2007; 48:258–269.
13. Witt KL, Tice RR, Wolfe GW, Bishop JB. Genetic damage detected in CD-1 mouse pups exposed perinatally to 3′-azido-3′-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatment. Environ Mol Mutagen 2004; 44:321–328.
14. Bishop JB, Witt KL, Tice RR, Wolfe GW. Genetic damage detected in CD-1 mouse pups exposed perinatally to 3′-azido-3′-deoxythymidine and dideoxyinosine via maternal dosing, nursing, and direct gavage. Environ Mol Mutagen 2004; 43:3–9.
15. Diwan BA, Riggs CW, Logsdon D, Haines DC, Olivero OA, Rice JM, et al. Multiorgan transplacental and neonatal carcinogenicity of 3′-azido-3′-deoxythymidine in mice. Toxicol Appl Pharmacol 1999; 161:82–99.
16. Dobrovolsky VN, Shaddock JG, Mittelstaedt RA, Bishop ME, Lewis SM, Lee FW, et al. Frequency of Hprt mutant lymphocytes and micronucleated erythrocytes in p53-haplodeficient mice treated perinatally with AZT and AZT in combination with 3TC. Environ Mol Mutagen 2007; 48:270–282.
17. Ayers KM, Torrey CE, Reynolds DJ. A transplacental carcinogenicity bioassay in CD-1 mice with zidovudine. Fundam Appl Toxicol 1997; 38:195–198.
18. Walker DM, Malarkey DE, Seilkop SK, Ruecker FA, Funk KA, Wolfe MJ, et al. Transplacental carcinogenicity of 3′-azido-3′-deoxythymidine in B6C3F1 mice and F344 rats. Environ Mol Mutagen 2007; 48:283–298.
19. IARC monographs on the evaluation of carcinogenic risks to humans. [Accessed March 2008].
20. Silverberg MJ, Neuhaus J, Bower M, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21:1957–1963.
21. Hanson IC, Antonelli TA, Sperling RS, Oleske JM, Cooper E, Culnane M, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:463–467.
22. Hankin C, Lyall H, Peckham C, Tookey P. Monitoring death and cancer in children born to HIV-infected women in England and Wales: use of HIV surveillance and national routine data. AIDS 2007; 21:867–869.
23. Brogly S, Williams P, Seage GR 3rd, Van Dyke R. In utero nucleoside reverse transcriptase inhibitor exposure and cancer in HIV-uninfected children: an update from the pediatric AIDS clinical trials group 219 and 219C cohorts. J Acquir Immune Defic Syndr 2006; 41:535–536.
24. Warszawski J, Tubiana R, Le Chenadec J, et al. Mother-to-child HIV transmission despite antiretroviral therapy in the ANRSFrench Perinatal Cohort. AIDS 2008; 22:289–299.
25. Desandes E, Clavel J, Berger C, Bernard JL, Blouin P, de Lumley L, et al. Cancer incidence among children in France, 1990–1999. Pediatr Blood Cancer 2004; 43:749–757.
26. Steliavora-Foucher E, Stiller CA, Lacour B, Kaatsch P. International classification of childhood cancer. Cancer 2005; 103:1457–1467.
27. Breslow NE, Day NE. Statistical methods in cancer research. Vol II: The design and analysis of cohort studies. IARC scientific publication no. 82, Lyon: IARC; 1987.
28. Parkin DM, Kramárová E, Draper GJ, Masuyer E, Michaelis J, Qureshi S, Stiller CA. International incidence of childhood cancer. Vol II. IARC scientific publications no 144; Lyon: IARC. pp. 365–367.
29. Peris-Bonet R, Martínez-García C, Lacour B, Petrovich S, Giner-Ripoll B, Navajas A, Steliarova-Foucher E. Childhood central nervous system tumours-incidence and survival in Europe (1978–1997): report from Automated Childhood Cancer Information System project. Eur J Cancer 2006; 42:2064–2080.
30. Antoneli CB, Ribeiro Kde C, Sakamoto LH, Chojniak MM, Novaes PE, Arias VE. Trilateral retinoblastoma. Pediatr Blood Cancer 2007; 48:306–310.
31. Hercules S, Ramesh V, Paramasivan S, Kodiarasan P, Kumar S. Holoventricular glioma in a child. Case report. J Neurosurg 2007; 106(2 Suppl):134–135.
32. Carter MM, Torres SM, Cook DL Jr, McCash CL, Yu M, Walker VE, Walker DM. Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells. Environ Mol Mutagen 2007; 48:239–247.
33. Anderson LM. Introduction and overview. Perinatal carcinogenesis: growing a node for epidemiology, risk management, and animal studies. Toxicol Appl Pharmacol 2004; 199:85–90.
34. Olivero OA, Shearer GM, Chougnet CA, Kovacs AA, Baker R, Stek AM, et al. Incorporation of zidovudine into cord blood DNA of infants and peripheral blood DNA of their HIV-1-positive mothers. Ann N Y Acad Sci 2000; 918:262–268.
35. Escobar PA, Olivero OA, Wade NA, Abrams EJ, Nesel CJ, Ness RB, et al. Genotoxicity assessed by the comet and GPA assays following in vitro exposure of human lymphoblastoid cells (H9) or perinatal exposure of mother-child pairs to AZT or AZT-3TC. Environ Mol Mutagen 2007; 48:330–343.
36. Witt KL, Cunningham CK, Patterson KB, Kissling GE, Dertinger SD, Livingston E, Bishop JB. Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV. Environ Mol Mutagen 2007; 48:322–329.
37. Senda S, Blanche S, Costagliola D, Cibert C, Nigon F, Firtion G, et al. Altered heterochromatin organization after perinatal exposure to zidovudine. Antivir Ther 2007; 12:179–187. Erratum in: Antivir Ther 2007; 12:429.

cancer; didanosine; HIV-1; lamivudine; nucleoside reverse transcriptase inhibitor; pregnancy; prophylaxis; zidovudine

© 2008 Lippincott Williams & Wilkins, Inc.